Key result
Albuminuria strongly predicts incident heart failure and disease progression independent of eGFR.
Why the study?
Does assessing albuminuria improve risk profiling for the development and progression of heart failure?
Does assessing albuminuria improve risk profiling for the development and progression of heart failure?
Albuminuria provides strong prognostic value for incident heart failure and its progression independent of eGFR, highlighting its potential utility in clinical practice and cardiovascular trials.
Although chronic kidney disease is characterized by low glomerular filtration rate (GFR) or albuminuria, estimated GFR (eGFR) is more widely utilized as a marker of risk profile in cardiovascular diseases, including heart failure (HF). The presence and magnitude of albuminuria confers a strong prognostic association in forecasting risk of incident HF as well as its progression, irrespective of eGFR. Despite the high prevalence of albuminuria in HF, whether it adds incremental prognostic information in clinical practice and serves as an independent risk marker, and whether there are any therapeutic implications of assessing albuminuria in patients with HF is less well-established. In this narrative review, we assess the potential role of albuminuria in risk profiling for development and progression of HF, strengths and limitations of utilizing albuminuria as a risk marker, its ability to serve in HF risk prediction models, and the implications of adopting albuminuria as an effective parameter in cardiovascular trials and practice.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2023) conducted a review in Heart failure. Albuminuria was evaluated. Albuminuria serves as a strong prognostic marker for forecasting the risk of incident heart failure and its progression, irrespective of estimated glomerular filtration rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: